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ABSTRACT 
Peripheral artery disease (PAD) is caused by atherosclerotic 
narrowing of the arteries supplying the lower limbs often 
resulting in intermittent claudication, evident as pain or 
cramping while walking. Supervised exercise training elicits 
clinically meaningful benefits in walking ability and quality 
of life. Walking is the modality of exercise with the strongest 
evidence and is recommended in several national and 
international guidelines. Alternate forms of exercise such as 
upper- or lower-body cycling may be used, if required by 
certain patients, although there is less evidence for these 
types of programmes. The evidence for progressive 
resistance training is growing and patients can also engage 
in strength-based training alongside a walking programme. 
For those unable to attend a supervised class (strongest 
evidence), home-based or ‘self-facilitated’ exercise 
programmes are known to improve walking distance when 
compared to simple advice. All exercise programmes, 
independent of the mode of delivery, should be progressive 
and individually prescribed where possible, considering 
disease severity, comorbidities and initial exercise capacity. 
All patients should aim to accumulate at least 30 min of 
aerobic activity, at least three times a week, for at least 
3 months, ideally in the form of walking exercise to near-
maximal claudication pain. 
INTRODUCTION 
Lower-limb peripheral artery disease (PAD) is 
an atherosclerotic cardiovascular disease in 
which the arteries that carry blood to the 
legs and feet become hardened, narrowed 
and/or obstructed by the build-up of 
atheroma.1 PAD is a common problem 
thought to affect over 200 million people 
worldwide.2 The total disease prevalence is 
approximately 13% of adults >50 years old, 
with major risk factors including smoking, 
diabetes and dyslipidaemia.3 
The most classic symptom of PAD is inter-
mittent claudication (IC). This is ischaemic 
muscle pain that usually presents in the calves 
(but can include the thighs or buttocks), is 
precipitated by exertion and relieved with rest 
(figure 1).4 This pain is thought to be due to 
a mismatch between the oxygen demand (of 
the working muscle) and an inadequate 
Summary box 
What is already known? 
► Supervised exercise training promotes clinically 
meaningful benefit in patients with intermittent 
claudication. 
► Walking as an exercise modality currently has the 
strongest level of evidence. 
What this study adds? 
► A concise summary of evidence and practical 
recommendations for exercise implementation for 
practioners, including example protocols for exercise 
training. 
► Progressive resistance training may be used as 
a supplement to walking programmes. 
blood supply (due to the narrowed arterial 
pathway).5 
Although PAD is progressive (in the patho-
logical sense), the clinical course is relatively 
stable.6 However, patients with PAD have 
a higher burden of cardiovascular disease 
and are at greater risk of major cardiovascular 
events.7 Another major issue for many 
patients is the severe decline in functional 
capacity (V̇ O2Peak) which are comparable to 
patients with heart failure and reduced ejec-
tion fraction.8 The reduction in functional 
capacity is commonly caused by a decline in 
walking capacity, which may be up to less than 
50% of healthy aged-matched controls.9 Fac-
tors influencing the walking distance or speed 
at which symptoms occur are multifactorial 
and include the site and severity of disease, 
walking pace, terrain, incline and footwear.10 
These physical constraints in turn have nega-
tive connotations on patient’s mental health 
and there are strong associations with depres-
sion, poor quality of life (QoL) and further 
avoidance of physical activity.11 12 This cycle 
of activity avoidance only leads to worsening 
functional ability and there is some evidence 
to suggest it also leads to an elevated mortality 
risk independent of disease severity and age.13 
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Figure 1 Intermittent claudication due to peripheral artery dis-
ease. Reproduced from Morlet et al3 with permission from BMJ 
Publishing Group Ltd. Note: Iliac or femoral artery disease 
can cause symptoms at multiple distal muscle sites. 
Treatment for patients with IC involves secondary pre-
vention of cardiovascular disease risk, including smoking 
cessation, diet changes, lipid modification, statin therapy, 
antiplatelet therapy and management of diabetes and 
hypertension. In addition to therapeutic intervention 
and lifestyle modification, the primary treatment to 
address the functional impairment outlined earlier is for 
patients to engage in appropriate exercise training, best 
achieved through a supervised exercise programme 
(SEP).14 This is supported by multiple consensus guide-
lines from various governing bodies.15–17 18 However, 
they lack detail and consistency (between guidelines) as 
to the appropriate principles of exercise such as intensity 
and progression (table 1), which impacts upon effective 
implementation. In addition to inconsistencies in the 
recommendations for exercise, there is also variability in 
the delivery of exercise programmes globally with some 
clinicians reporting lack of expertise or support to guide 
the exercise delivery.19–21 
This guideline for practitioners aims to accompany 
these consensus guidelines to provide a succinct but 
more detailed overview of, and recommendations for, 
exercise prescription and training for IC. While we 
appreciate that delivery and provision will vary, the key 
exercise prescription components will remain and as 
such, this document will be relevant for exercise practi-
tioners worldwide. In addition, we provide advice for the 
implementation of the exercise prescription guidelines 
into clinical practice (table 2), which also includes infor-
mation on structured alternatives when SEPs are not 
available19 23 
Walking ability 
Measures of walking ability include pain-free and maxi-
mum walking distance (or time) obtained during standar-
dised treadmill testing and/or the distance covered in the 
6-min 30-m corridor walk test. Several treadmill protocols 
have been reported, but the ‘Gardner/Skinner’ incre-
mental protocol is most commonly used.26 27 This 
involves a constant speed of 3.2 km/hour at a 0% grade, 
increasing by 2% every 2 min. The advantage of using 
a treadmill test is that it can be standardised (ie, speed of 
treadmill, grade of treadmill), although it may not be as 
reflective of normal everyday walking (6-min walking 
distance).28 29 
Quality of life 
Several generic and condition-specific questionnaires 
have been used to assess QoL. The most validated, respon-
sive and reliable questionnaires in the IC population are 
the Short-Form-36 (SF-36) and King’s College Hospital’s 
VascuQoL questionnaires, respectively.30 31 Additional 
and commonly used questionnaires include the Walking 
Impairment Questionnaire32 and the Peripheral Artery 
Questionnaire.33 
EXERCISE TRAINING 
Benefits of exercise training 
A recent Cochrane review concluded that there is high-
quality evidence showing that SEPs (a variety of regimes) 
elicit important improvements in both pain-free and max-
imum walking distance compared with no-exercise con-
trol in people with IC.14 A meta-analysis of nine trials 
(n=391) showed a mean between-group difference in 
pain-free walking distance at follow-up of 82 m (95% CI 
72 to 92 m [follow-up ranging 6 weeks to 2 years]) and 
maximum walking distance of 120 m (95% CI 50.79 to 
190 m). The most commonly tested mode of exercise was 
walking, with one cycling intervention. The correspond-
ing difference for maximum walking distance was 120 m 
(95% CI 51 to 190 m; 10 trials, n=500). Improvements of 
this magnitude are likely to represent clinically meaning-
ful changes in ambulatory function.34 
The same review also reported that there was moderate-
quality evidence for improvements in physical and mental 
aspects of QoL, assessed using the SF-36.14 A meta-analysis 
of data at 6 months of follow-up showed the physical 
component summary score to be 2 points higher in exer-
cise versus control (95% CI 1 to 3; 5 trials, n=429). The 
corresponding difference for the mental component 
summary score was 4 points (95% CI 3 to 5; 4 trials, 
n=343). Such differences have the potential to be clini-
cally meaningful.14 
Modes of exercise 
In most studies, SEPs have involved treadmill or track 
walking at an intensity that elicits moderate to maximal 
claudication pain.35 There is a strong evidence-base for 
this type of training, and clinical guidelines cite it as the 
preferred modality (eg, The Trans-Atlantic Inter-Society 
Consensus Document on Management of Peripheral 
Arterial Disease II).15 As of 2011, alternate exercise mod-
alities had not been extensively studied.36 In 2005, 
a randomised trial of 104 participants provided evidence 
that a 24-week intervention of either cycling or arm-
cranking is viable alternatives for improving maximum 
walking distance (shuttle-walk) up to 29% and 31%, 
respectively.37 These modalities may be most useful for 
patients who are unwilling/unable to walk because of 
severe pain or deconditioning.38 Resistance training 
may also have a complementary role (eg, for improving 
muscular strength)39; however, at this point, interna-
tional guidelines suggest it should not be used as 
a substitute for aerobic exercise because its impact on 
Harwood AE, et al. BMJ Open Sp Ex Med 2020;0:e000897. doi:10.1136/bmjsem-2020-000897 
B
M
J O
pen S
port E
xerc M
ed: first published as 10.1136/bm
jsem
-2020-000897 on 6 N
ovem
ber 2020. D
ow
nloaded from
 http://bm
jopensem
.bm
j.com
/ on N
ovem
ber 9, 2020 at U
niversity of
S
ydney Library. P
rotected by copyright.
2 
T
ab
le
 1
 
V
as
cu
la
r 
su
rg
er
y 
gu
id
el
in
e 
re
co
m
m
en
d
at
io
ns
 fo
r 
ex
er
ci
se
S
up
p
le
m
en
ta
ry
R
ec
o
m
m
en
d
at
io
n 
Fr
eq
ue
nc
y 
In
te
ns
it
y 
T
yp
e 
T
im
e 
D
ur
at
io
n 
P
ro
g
re
ss
io
n 
S
up
er
vi
si
o
n 
Lo
ca
ti
o
n 
ex
er
ci
se
s 
G
ui
d
el
in
e
TA
S
C
 II
, 2
00
71
5
 
3 
×
 p
er
S
p
ee
d
 a
nd
 g
ra
d
e
In
te
rm
itt
en
t
30
 m
in
N
ot
In
cr
ea
se
 s
p
ee
d
/
N
ot
 r
ep
or
te
d
 
N
ot
N
ot
 r
ep
or
te
d
 
w
ee
k
th
at
 in
d
uc
es
tr
ea
d
m
ill
in
cr
ea
si
ng
 u
p
 to
re
p
or
te
d
 
gr
ad
e 
if 
p
at
ie
nt
 c
an
re
p
or
te
d
 
(ty
p
ic
al
ly
) 
cl
au
d
ic
at
io
n 
w
ith
in
w
al
ki
ng
 
60
 m
in
 
w
al
k 
fo
r 
m
or
e 
th
an
3–
5 
m
in
 
10
 m
in
 
A
H
A
/A
C
C
, 2
01
61
7
 
3 
×
 p
er
M
ax
im
um
–
 
In
te
rm
itt
en
t
30
–
45
 m
in
M
in
im
um
N
ot
 r
ep
or
te
d
 
S
up
er
vi
se
d
 b
y
H
os
p
ita
l/
N
ot
 r
ep
or
te
d
 
w
ee
k 
m
od
er
at
e
w
al
ki
ng
 
p
er
 s
es
si
on
, w
ith
of
a 
q
ua
lif
ie
d
ou
tp
at
ie
nt
cl
au
d
ic
at
io
n 
w
ar
m
 u
p
 a
nd
12
 w
ee
ks
 
he
al
th
ca
re
fa
ci
lit
y 
co
ol
 d
ow
n 
p
ro
fe
ss
io
na
l 
E
C
S
, 2
01
71
8
 
N
ot
N
ot
 r
ep
or
te
d
 
W
al
ki
ng
 
M
in
im
um
A
t l
ea
st
N
ot
 r
ep
or
te
d
 
S
up
er
vi
se
d
 
N
ot
C
yc
lin
g,
 s
tr
en
gt
h
re
p
or
te
d
 
3 
ho
ur
s/
w
ee
k 
3 
m
on
th
s 
re
p
or
te
d
 
tr
ai
ni
ng
 a
nd
up
p
er
-a
rm
er
go
m
et
ry
 
N
IC
E
 1
47
20
18
1
6
 
N
ot
M
ax
im
al
 p
ai
n 
W
al
ki
ng
 
2 
ho
ur
s/
w
ee
k 
3 
m
on
th
s 
N
ot
 r
ep
or
te
d
 
S
up
er
vi
se
d
 
N
ot
N
ot
 r
ep
or
te
d
 
re
p
or
te
d
 
re
p
or
te
d
 
R
A
C
G
P
, 2
01
32
2
 
3–
5 
×
 p
/w
 
P
ai
n 
In
te
rm
itt
en
t
30
 m
in
N
ot
N
ot
 r
ep
or
te
d
 
S
up
er
vi
se
d
 
N
ot
N
ot
 r
ep
or
te
d
 
w
al
ki
ng
 
in
cr
ea
si
ng
 to
re
p
or
te
d
 
re
p
or
te
d
 
60
 m
in
 
A
C
C
; A
H
A
; E
C
S
; N
IC
E
; R
A
C
G
P
; T
A
S
C
. 
Open access 
Harwood AE, et al. BMJ Open Sp Ex Med 2020;0:e000897. doi:10.1136/bmjsem-2020-000897 3 
B
M
J O
pen S
port E
xerc M
ed: first published as 10.1136/bm
jsem
-2020-000897 on 6 N
ovem
ber 2020. D
ow
nloaded from
 http://bm
jopensem
.bm
j.com
/ on N
ovem
ber 9, 2020 at U
niversity of
S
ydney Library. P
rotected by copyright.
Open access 
Table 2 Summary of exercise prescription recommendations 
To improve walking capacity, claudication symptoms and quality of life, and for secondary 
Exercise rationale prevention of cardiovascular disease 
Provider The programme should have a designated clinical lead (eg, vascular surgeon, physician or 
nurse specialist). Exercise professionals who wish to work in this area should possess the 
essential competencies and minimum qualifications as per the country of work. Professional 
standards of accredited exercise physiologists should include detailed knowledge of 
pathophysiology, exercise physiology and exercise training for patients with IC. Some of these are 
specified in the following BACPR Position Statement (UK Based):http://www.bacpr.com/ 
resources/51A_EPG_Position_Statement.pdf 
Mode of delivery The exercise should ideally be delivered through an on-site supervised programme. The exercise 
prescription should be individually tailored based on an initial assessment; however, several 
patients may be supervised at the same time. A facilitated, self-managed exercise programme with 
embedded behaviour change techniques is a reasonable alternative for people who prefer this 
approach or are unable to access an on-site programme, or for longer-term benefit after 
a supervised programme is completed. Details of a structured education programme that promotes 
self-managed walking exercise can be found here.24 Additional information for home-based 
exercises can be found here: (https://circulationfoundation.org.uk/news/COVID-19-special) 
Unstructured, unsupervised exercise approaches that consist solely of basic advice to walk 
or exercise more are not effective. 
Setting On-site programmes can be delivered in various settings including hospital- or community-based 
exercise physiology or physiotherapy clinics or community exercise facilities. Self-managed 
programmes can be conducted in a setting that suits the individual. 
Materials Assessment tools: Motorised treadmill with adjustable incline to allow incremental exercise 
testing (eg, ‘Gardner’ protocol) to determine pain-free and maximum walking distances or, if 
unavailable, procedures and instructions for an alternative functional capacity test (eg, 30 m 6-min 
corridor walk test); questionnaires for assessing patient-perceived ambulatory function (eg, 
WELCH questionnaire), and generic and condition-specific quality of life (eg, SF-36, VascuQoL and 
Walking Impairment uestionnaires, respectively). Optional—equipment to assess vascular status 
(eg, ankle-brachial index) and cardiovascular disease risk (eg, blood pressure, lipid profile). 
Exercise equipment: Motorised treadmills with adjustable incline or space for over-ground 
walking (preferably indoor and air-conditioned). Optional for aerobic exercise—upper and lower 
limb ergometers. Optional for resistance exercise—weights machines, dumbbells. 
Intensity-monitoring equipment: Five-point claudication pain scale, exertion scale (eg, 6‒20point 
Borg Rating of Perceived Exertion Scale), heart rate monitors, manual sphygmomanometer and 
stethoscope. 
Walking exercise Programme duration: At least 3 months 
guidelines Frequency: ≥3 times/week 
Claudication pain endpoint: Based on current evidence, patients should be advised to walk to the 
point of near-maximum leg pain (ie, 4–5 on claudication pain scale); however, preliminary evidence 
suggests that walking only to the onset of ischaemic leg pain may also be beneficial for patients 
reluctant to walk at higher levels of pain 
Pattern: Following a warm-up period, the patient should walk at a speed and grade that induces 
claudication pain within 3–5 min. The patient is instructed to stop walking and rest when his or her 
claudication pain reaches a moderate-to-strong level. When the claudication has abated, the 
patient resumes walking until a moderate-to-strong claudication pain recurs. This cycle of exercise 
and rest is ideally repeated for at least 30 min. In subsequent visits, the speed or grade of walking is 
increased if the patient is able to walk for ≥10 min without reaching moderate claudication pain. For 
those patients who start at a lower level of claudication pain (1–3/5), as the patient tolerates it, they 
should be encouraged to increase the intensity of pain achieved as a progression tool. 
Duration per session: Many patients with IC may need to start with just 10–15 min of walking 
exercise per session. In this situation, the duration of exercise should be increased by 5 min each 
week, until the patient is walking for at least 30 min per session. Patients who can walk for more 
than 30 min per session should be encouraged to increase the exercise duration to 45–60 min. They 
should also be encouraged to include other modes of exercise to work on improving 
cardiorespiratory fitness and muscular strength 
Continued 
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Table 2 Continued 
Exercise rationale To improve walking capacity, claudication symptoms and quality of life, and for secondary 
prevention of cardiovascular disease 
Upper and lower limb May be considered as alternative aerobic exercise strategies for improving walking ability and 
ergometry quality of life. May also have the potential to provide a greater cardiorespiratory stimulus than 
walking exercise in individuals with severe claudication. 
Example protocol: Ten sets of 2 min of upper or lower extremity ergometry conducted twice 
weekly for at least 3 months. Intensity should be moderate or Borg RPE 13–14 (6–20 scale) 
Resistance exercise Though evidence is increasing, resistance exercise is yet to be included in international guidelines 
as a sole therapy, it is purely recommended as an adjunct for now. It therefore should be considered 
as complementary (eg, for targeting improved strength or reduced falls risk), but not as 
a replacement for aerobic exercise because its impact on walking ability appears modest at best. 
Example protocol: Moderate-to-high intensity (Borg exertion rating of 14–16), 6–8 exercises (leg 
press, Knee flexion, knee extension, calf press, chest press, seated row) targeting the major muscle 
groups of the upper and lower body, 2–4 sets of 10–15 repetitions per set, 2–3 sessions per week. 
Other Circuit-based training may be a practical way of delivering a combination of aerobic and resistance 
exercises when circumstances necessitate group-based training and is an effective tool for 
improving both muscle strength and cardiorespiratory fitness, which are both related to reduced 
cardiovascular and all-cause mortality.25 
Safety issues An initial risk assessment should occur as per Appendix E of the following ACPICR Standards 
document https://www.acpicr.com/data/Page_Downloads/ACPICRStandards.pdf . Exercise is 
contraindicated by foot ulcers and limb pain at rest (ie, critical limb ischaemia). As patients increase 
their walking ability, there is the possibility that cardiac signs and symptoms may appear (eg, 
dysrhythmia, angina). These events should prompt further clinical assessment to ensure safety 
continuing. Clinical assessment should also be considered when a patient undertakes a mode of 
exercise that is not limited by claudication pain. 
ACPICR; BACPR; IC; RPE; SE-36, Short-Form-36; VascuQoL; WELCH. 
walking distance appears modest (eg, McDermott et al 
2009). Nevertheless, there is emerging evidence to sup-
port its efficacy, and it should no longer be a mode of 
exercise that is ignored. A recent systematic review and 
meta-analysis (n=826; 363 resistance trained) demon-
strated that resistance training (in comparison to control) 
can significantly improve both maximum walking dis-
tance via constant treadmill testing (standardised mean 
difference (SMD) 0.51 [95% CI 0.23 to 0.79]) and max-
imum walking distance via progressive treadmill testing 
(SMD 0.45 [95% CI 0.08 to 0.83]). Only 6-min claudica-
tion onset time (not pain-free treadmill distance) was 
significantly improved with resistance training (mean dif-
ference (MD) 82 m [95% CI 40.91 to 123.54).39 
Frequency of exercise 
A comparison of different training frequencies for 
patients with IC has not been investigated in a single 
study. The 1995 meta-analysis of Gardner and Poehlman 
suggested that an exercise frequency of ≥3 sessions per 
week was associated with better outcomes compared with 
<3 times per week, although it should be noted that it 
pooled data from randomised controlled trials and 
uncontrolled studies.40 In addition, the 2004 review of 
Bulmer and Coombes also identified three sessions per 
week as the optimal frequency for maximum improve-
ments in walking distance.41 Conversely, a meta-analysis 
in 2012 including 1054 patients did not identify an opti-
mal frequency for programmes.42 The authors of the 
2012 meta-analysis do note, however, that a SEP with 
three sessions per week (in combination with duration 
of programme and session) ‘would give the best results’.42 
Therefore, frequency of SEPs should aim to be at least 
three times per week, which is in line with common 
physical activity guidelines for the general population.17 
Duration of programme 
No standardised duration of programme for patients with 
IC has been identified, with exercise programme length 
ranging from as little as 2 weeks to as many as 
18 months.35 Gardner et al (2012) measured outcomes 
at 2, 4 and 6 months (n=80) and demonstrated that 
exercise-mediated improvements in pain-free and maxi-
mum walking distances were largely achieved in the first 
2 months.43 Additional meta-analysis has also demon-
strated that improvements in treadmill walking occur 
following 3 months of supervised exercise.41 44 45 It may 
be likely that the optimal prescription is difficult to eluci-
date due to heterogeneity of studies, including differ-
ences in frequency, intensity and type of the exercise. 
Currently, we recommend that programmes should be 
at least a minimum of 12 weeks in duration. 
Intensity of exercise 
Exercise intensity is commonly prescribed on the basis of 
heart rate, rating of perceived exertion, or V̇ O2peak 
obtained via exercise stress testing,46 and may be classified 
as low, moderate or vigorous based on the American 
College of Sports Medicine guidelines.47 There is limited 
information on the appropriate intensities of exercise 
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programmes for patients with PAD.17 48 However, a meta-
analysis by Parmenter et al (2015) investigated the rela-
tionship between exercise intensity, V̇ O2peak (ie, aerobic 
capacity) and maximal walking distance, and demon-
strated that the greatest improvements occurred when 
exercise intensity was between 70% and 90% HRmax 
(ie, vigorous according to the American College of Sports 
Medicine guidelines).49 A further systematic review by 
Pymer et al (2019) focusing on high-intensity exercise 
identified four studies that prescribed exercise on the 
V̇ O2peak or HRmax achieved during baseline testing. 
Overall, six studies demonstrated significant improve-
ments in treadmill maximum walking distances com-
pared with a control group (generally consisting of 
exercise advice alone).50 However, further research is 
required to establish the relationship between intensity 
(moderate vs vigorous) and walking improvements and 
compare those findings to SEPs. 
Claudication pain scale 
Relatively few trials have used classically defined measures 
of exercise intensity as described earlier, and for patients 
with PAD, there is a common misconception between 
exercise ‘intensity’ and severity of leg pain or 
discomfort.51 Most reported trials in the literature use 
the claudication pain scale to instruct patients when to 
stop exercising and not exercise intensity markers such as 
heart rate. The claudication pain scale is a continuous 
scale from 1, indicating no pain, to 5 indicating severe 
pain,49 with trials often instructing patients to walk to 
near-maximal pain levels. 
Three studies have specifically investigated the relation-
ship between ‘intensity’ (based on pain) and walking 
outcomes.52–54 Mika et al (2013) used different intensities 
corresponding to scores on the pain scale and matched 
exercise duration in 60 patients.53 Gardner et al (2005) 
prescribed intensity as ‘high—80%’ or ‘low—40%’ based 
on the maximal grade achieved at baseline in 31 
patients.52 Finally, Novakovic et al (2019) randomised 36 
patients to either moderate or pain-free walking, with 
moderate training prescribed on 70% of the patients 
predicted HRmax.54 For all studies, outcomes including 
pain-free and maximum walking distance did not differ 
between the intensities prescribed. This may highlight 
that the volume of exercise (and not intensity prescribed) 
is perhaps the most important factor for improving walk-
ing distance in patients with IC.36 49 55 With regard to 
pain, overall the current evidence seems to favour 
patients walking near maximal pain for beneficial out-
comes. However, walking to no pain, or minimal pain, 
may also been shown to be effective for this cohort.54 55 
Indeed, a meta-analysis by Parmenter et al (2011) showed 
that walking without inducing claudication pain pro-
duced significant improvements in initial claudication 
distance and also improved absolute claudication 
distance.36 Additionally, a meta-analysis (six studies) in 
2015 demonstrated that improvements in cardiorespira-
tory fitness were obtained when walking to mild pain (MD 
0.79 mL/kg/min [95% CI 0.45 to 1.14]).49 Current 
recommendations are if patients can tolerate, then walk-
ing to moderate pain (i.e 4–5 on the claudication scale) 
may be suitable. If patients are unable to tolerate higher 
levels of pain on the claudication scale, then they can walk 
to low levels of pain, provided the volume of exercise is 
sufficient,47 which may improve adherence levels. 
Supervision 
Despite consistent evidence demonstrating the clinical 
effectiveness of SEPs, a European survey conducted in 
2012 demonstrated that approximately 30% of the 
respondents had access to a supervised programme,56 
with similar availability in the UK.19 Similar evidence has 
recently emerged from the USA with 54% of the respon-
dents stating no exercise to a SEP.20 These low provision 
rates may be attributed to several factors including fund-
ing provision, facilities, referral pathways, resources and 
a lack of trained staff.19 23 
A 2014 review noted uncertainty regarding the benefits 
of SEPs over unsupervised exercise, especially regarding 
QoL.51 Despite the apparent superiority of SEPs, there is 
still a need to develop alternative programmes, given that 
supervised programmes may be ‘unpopular’ with patients 
due to financial, time or transport limitations,57 58 or 
simply because they are looking for a ‘quick fix’.59 As 
supervised programmes may be unavailable to a large 
proportion of patients, the development of alternative 
home-based or ‘self-facilitated’ programmes have been 
increasingly trialled. These types of interventions have 
varied in content but include psychological 
interventions,60 such as cognitive behavioural changes,61 
step-monitoring62 and patient education.24 
Home exercise programmes 
Evidence for home-based or self-managed programmes is 
currently conflicting. In 2013, a systematic review 
reported that there was low-level evidence to suggest 
home-based programmes can improve walking distance 
and QoL in comparison to walking advice or non-
exercise.63 In 2018, a Cochrane review including 21 studies 
and 1400 patients, reported that there was high-quality 
evidence showing greater improvements in maximum 
walking distance (measured via treadmill testing) at 3 
months among patients enrolled in a SEP versus a home-
based programme (95% CI 0.12 to 0.65), or in patients 
who received walking advice only (95% CI 0.53 to 1.07).64 
This translates to walking distance improvements of 
between 120 and 210 m in favour of supervised exercise, 
respectively, with similar improvements maintained at 6 
and 12 months. However, the prescription of exercise 
may influence the magnitude of effect, possibly due to 
training specificity.49 Conversely, the meta-analysis of 
QoL outcomes showed no marked differences between 
supervised exercise and home exercise programmes. In 
a recent randomised trial, McDermott et al (2018) consid-
ered the efficacy of home-based exercise (n=99) with wear-
able technology and telephone coaching versus no 
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exercise advice and found no difference home exercise 
and control.65 Therefore, further research is required to 
evaluate the specific components of home-based interven-
tions to maximise patient benefit (ie, wearable technology, 
on-site visits, etc). 
Safety 
There may be a misconception that exercise training may 
be unsafe in patients with PAD. Indeed, 70% of the vas-
cular surgeons in one survey thought that cardiovascular 
comorbidities or aorto-iliac stenosis or occlusions were 
relative contraindications to exercise.66 Gommans et al 
(2015) explored the safety of supervised exercise training 
(via any exercise modality) and reviewed adverse event 
data from clinical trials.67 Seventy-four trials were 
included, representing 82 725 hours of training in 2876 
patients with a mean age of 64 years (range 54–76 years). 
Nine adverse events were reported, six of cardiac, two of 
non-cardiac origin and one fatal adverse event (myocar-
dial infarction). This resulted in an all-cause complication 
rate of one event per 10 340 patient-hours. The total non-
cardiac and cardiac event rate was 1 per 13 788 patients 
and 1 per 41 363 hours. The study concluded that super-
vised exercise training is safe for people with IC due to 
a low all-cause complication rate, and routine cardiac pre-
screening is not required.67 However, it should be noted 
that patients participating in clinical trials might not be 
a true representation of the overall population. This may 
be due to strict exclusion/inclusion criteria screening out 
patients with extensive comorbidities. It would be bene-
ficial to have observational data for adverse events in 
routine SEPs, to fully elucidate the all-cause complication 
rates. In addition, it is important to note, that as 
a patient’s exercise tolerance, pain tolerance and walking 
ability improve, this may begin to unmask underlying 
signs and symptoms of coronary artery disease. While 
not routine practice, cardiac screening may also be con-
sidered when patients are engaging in an exercise mod-
ality that may not elicit claudication pain such as cycling 
or when they are engaging in higher-intensity exercise 
programmes. In general, contraindications to participa-
tion in an exercise programme include uncontrolled 
hypertension, unstable angina or other uncontrolled 
arrhythmias. Relative contraindications include known 
obstructive coronary disease, acquired or advance heart 
block. A comprehensive list of both absolute and relative 
contraindications can be found in the ‘American College 
of Sports Medicine Guidelines for Exercise Testing and 
47 68 Prescription’. 
APPLICATION TO PRACTICE 
Recommendations for exercise training 
All prospective patients should be clinically assessed, and 
risk stratified to ensure that they do not have any contra-
indications to the exercise therapy, and to document 
comorbidities that may need to be accounted for, in 
order to individualise the exercise programme. Patient 
ability and preference should also be taken into account 
when prescribing the exercise programme. Clinical 
assessment should be repeated as exercise tolerance 
improves to ensure that the training intensity is sufficient 
to ensure ongoing patient safety. Any exercise pro-
gramme should ideally be delivered through an on-site 
supervised programme with clinical oversight. However, 
a facilitated, self-managed exercise programme involving 
behaviour change techniques is a reasonable alternative 
for patients who prefer this approach or are unable to 
access supervised exercise.24 The core modality for SEPs 
should be walking; however, other modes are also effica-
cious for those who cannot tolerate walking programmes, 
as outlined in table 2. Alternative modes include arm 
cranking, cycling, pole-striding and progressive resistance 
training. A structured programme should involve walking 
at an intensity that elicits moderate-to-strong claudication 
pain and should be conducted for a minimum of 
3 months, involving at least three sessions of 30–45 min/ 
week. Initial exercise prescription should be based on 
actual baseline maximum walking distance. Further evi-
dence-based recommendations for exercise training are 
provided in table 2. However, if patients struggle with the 
maximum intensity of pain prescribed, then walking at 
lower pain levels will also lead to improvements in walking 
ability/distance.36 55 
During exercise training sessions, acute responses to 
exercise should be monitored to inform the exercise pre-
scription, including heart rate, blood pressure (in the first 
few exercise sessions), perceived exertion and claudica-
tion pain. The continuous monitoring of blood pressure 
is not recommended but should be revaluated if the 
intensity or mode of exercise changes. It is recommended 
that heart rate may be continuously monitored, and 
blood pressure, perceived exertion and claudication 
pain are recorded intermittently when the patient stops 
exercises (if interval walking) or if any signs or symptoms 
(such as dizziness are present). Finally, programme entry 
and exit assessments should be performed to determine 
changes in patient outcomes, including walking distance 
(primarily 6-min walk test) and QoL. 
To support the provision and uptake of exercise, along-
side this guideline an infographic of key messages has 
been developed that may be used as a poster or handout 
in clinic; particularly where patients cannot access 
a supervised programme.69 
SUMMARY 
Exercise training is a safe, effective and low-cost interven-
tion for improving walking ability in patients with IC. 
Additional benefits may include improvements in QoL, 
muscle strength and cardiorespiratory fitness. Clinical 
guidelines advocate supervised exercise training as 
a primary therapy for IC, with walking as the primary 
modality. However, evidence is emerging for the role of 
various other modes of exercise including cycling and 
progressive resistance training to supplement walking 
training. In addition, there is emerging evidence for 
home-based exercise programmes. Revascularisation or 
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drug treatment options should only be considered in 
patients if exercise training provides insufficient sympto-
matic relief. 
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